ResMed (MIL:1RMD) Beta: N/A (As of Jul. 07, 2026)


MIL:1RMD ResMed Inc MIL:1RMD
79 GF Score
Price €188.95
GF Value €236.73
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), ResMed's Beta is Not available.

ResMed  (MIL:1RMD) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

ResMed Beta Related Terms

ResMed Beta Historical Data

* Premium members only.

The historical data trend for ResMed's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Beta Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIL:1RMD
79GF Score
ResMed Inc MIL:1RMD
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is ResMed (MIL:1RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of €188.95 is trading 20.2% below its estimated GF Value™ of €236.73. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for MIL:1RMD:

  • Beta: N/A
  • GF Value™: €236.73 vs. price of €188.95 (20.2% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the MIL:1RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
79GF Score

Get the complete analysis for MIL:1RMD

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€188.95
Price
€236.73
GF Value